Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.86 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.86 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.86 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.86 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.86 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.86 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.86 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.86 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.86 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.86 |
| ▸ | ABL1 | P00519 | 12/20 | 0.83 |
| ▸ | SRC | P12931 | 9/20 | 0.83 |
| ▸ | LCK | P06239 | 5/20 | 0.83 |
| ▸ | EGFR | P00533 | 3/20 | 0.83 |
| ▸ | FYN | P06241 | 3/20 | 0.83 |
| ▸ | YES1 | P07947 | 3/20 | 0.83 |
| ▸ | LYN | P07948 | 3/20 | 0.83 |
| ▸ | HCK | P08631 | 3/20 | 0.83 |
| ▸ | KIT | P10721 | 3/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750253 | 1.00 | HDAC3 (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL29817345 | 0.99 | HDAC3 (0.85) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14416600 | 0.94 | HDAC3 (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13626293 | 0.93 | ABL1 (0.89) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1146496 | 0.92 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28914780 | 0.92 | ABL1 (0.88) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19362612 | 0.92 | ABL1 (0.85) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16569731 | 0.92 | ABL1 (0.84) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25243991 | 0.91 | HDAC3 (0.87) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1147166 | 0.91 | HDAC3 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-12577556-B2 | Perturbation beads for use in assays | Zafrens Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240361310-A1 | Capture Beads for Use in Assays | Zafrens Inc. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240327824-A1 | Perturbation Beads for Use in Assays | Zafrens Inc. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11913944-B2 | Photoaffinity probes | PROMEGA CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11913944-B2 | Photoaffinity probes | PROMEGA CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-08-31 | — | — | US | disclosed |
| EP-4232023-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-2492355-A1 | Tissue protective erythropoietin receptor (nepor) and methods of use | Life Biosystems GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2109690-B1 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2435581-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GmbH (DE) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136192-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
| US-7622473-B2 | 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622473-B2 | 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2007106879-A2 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | UGT1A6, PAH, CYP2B6 | HDAC3 921/4885HDAC4 982/4885HDAC1 1279/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | HDAC3 2314/4885HDAC4 3363/4885HDAC1 1256/4885 |
| US-12577556-B2 | Perturbation beads for use in assays | PLK1, TOP1, MBNL1 | HDAC3 4168/4885HDAC4 3502/4885HDAC1 3733/4885 |
| US-20230271983-A1 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | KIT, MACF1, IK | HDAC3 4139/4885HDAC4 3621/4885HDAC1 4464/4885 |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | HDAC3 1404/4885HDAC4 2638/4885HDAC1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.